[Correspondence] Primary medical therapy for BRAFV600E-mutant melanoma brain metastases—is this good enough? – Authors' reply

Improving outcomes in patients with melanoma brain metastases remains a major challenge. Tim J Kruser and Michael A Vogelbaum state that the results of COMBI-MB1 should be interpreted with caution because the frequency and durability of responses "pale in comparison" to recent retrospective studies of patients with melanoma brain metastases treated with stereotactic radiosurgery (SRS) and BRAF inhibitors. Of note, Kruser and Vogelbaum incorrectly state that COMBI-MB was restricted to patients with "small, asymptomatic, <5 lesions".

http://ift.tt/2eMX73F